Genentech
Executive Summary
Surgery and Thrombolysis for Ischemia of the Lower Extremity trial halted after interim analysis of first 300 patients shows advantage for surgery over thrombolytic therapy for treatment of peripheral arterial occlusion (PAO). According to Genentech, the thrombolytic arm (using either Genentech's Activase or Abbott's Abbokinase) was hampered by a "mechanical difficulty" in "placing the catheter delivering the drug into the clot." Genentech said it will continue to study Activase for PAO subpopulations. The company plans to begin trials in patients at high risk of amputation and in acute PAO patients during the current quarter.
|
Surgery and Thrombolysis for Ischemia of the Lower Extremity trial
halted after interim analysis of first 300 patients shows advantage
for surgery over thrombolytic therapy for treatment of peripheral
arterial occlusion (PAO). According to Genentech, the thrombolytic
arm (using either Genentech's Activase or Abbott's Abbokinase) was
hampered by a "mechanical difficulty" in "placing the catheter
delivering the drug into the clot." Genentech said it will continue
to study Activase for PAO subpopulations. The company plans to
begin trials in patients at high risk of amputation and in acute
PAO patients during the current quarter. |